spacer
home > ebr > Summer 2002
PUBLICATIONS

European Biopharmaceutical Review

ebr
Summer 2002
At the cutting edge of the latest industry developments, Samedan is adept at keeping the information you need at your fingertips. EBR provides a unique platform of communication for the market across Europe, North America and the rest of the developed world. To find out what's hot in the world of of biopharmaceuticals, take a look below at the range of articles featured in this issue of EBR.
   
Text
PDF
In her Editor's Letter, Dr Helen Abbott gives us a brief synopsis of the range and content of this issue  
view
bullet
STRATEGY AND FINANCE
What are the driving factors and the change in management approach needed to negotiate the risk transfer issues the industry is facing? Howard Pearson, a Director and Head of the Science and Technology Team at The Miller Insurance Group, presents some of the answers in Preventing Risk Becoming a Crisis  
view
Dr Benjamin Jones, Business Development Manager at Huntingdon Life Sciences Ltd, comments on the value of contract research organisations and the growth of contract research in the context of the biopharmaceutical industry, in his article Contract Development - Industry Spend and Value  
view
In the current climate of consolidation within the biomedical sector, many companies may find that they need adopt a flexible approach to their business strategy or face losing their investments. Martin Austin, Director of European Operations, Paul Royalty Funds, at Paul Capital Partners, presents A Case for Alternative Financing in Biomedical Companies INDUSTRY DYNAMICS  
view
The success of large pharmaceutical companies primarily reflects their development and marketing of blockbuster drugs, but Where is the Blockbuster Market Heading? Dr Linda McNamara, Healthcare Strategy Analyst at Datamonitor provides a must read analysis of the current and future blockbuster market  
view
Dr Helen Abbott, Senior Consultant at Technomark Consulting Services, reviews Beyond Borders - Ernst & Young's Global Biotechnology Report 2002  
view
Dr Abbott's been busy this month! Read her review of the 2nd European C21 BioInvestor Conference (EC21), Munich, 2002  
Science and Innovation
Dr Andreas Rьhlmann, European Bioinformatics and Microarray Specialist at Agilent Technologies, examines current therapeutic developments for the treatment of central nervous system defects, in Gene Therapy for Damaged Nerves  
view
If the dream of proteomics is the identification and characterisation of all proteins, then the nightmare is the number of unique functional protein structures. Dr Lucio van Rooijen, Vice President Business Development, and Dr Josef Schwarz, Director of Protein Profiling at Xzillion, examine the Ongoing Challenges in Proteomics  
view
Keith Chidwick, Consultant at Technomark Consulting Services, reviews Shayla Walmsley's Scrip report in Delivering Gene Therapy - A Review  
view
Dr Frank Kooy of the Mental Retardation Research Group, Department of Medical Genetics, University of Antwerp in Belgium, explores the Genetic Aspects of Mental Retardation, explaining why a better insight into the molecular causes of retardation could lead to realistic therapies for the mentally handicapped  
view
In Proteolytic Enzymes as Therapeutic Targets, Dr Urs Lüthi, Senior Scientist at ESBATech, reviews a number of methods that have allowed molecular cloning of secretases and discusses various approaches to discovering specific secretase inhibitors
 
view
Screening, production and test systems are crucial for the survival of drugs through the development process, making careful selection of these systems vital. Michael Zang-Gandor, CEO of Eugenex Biotechnologies GmbH, explores these selection processes in Finding the Meaning of the Gene  
view
bullet
Legal, Regulatory and Public Policy
The debate about the safety and ethics of gene therapy has always been controversial. Daniel Gooch, Jayne Spink and John Connolly at the Department of Health in London, examine The Role of the Gene Therapy Advisory Committee in the Ethical and Regulatory Oversight of UK Gene Therapy  
view
The UK Government has demonstrated a determination to increase the level of R&D investment by UK industry. Dawn Primarolo MP, Paymaster General for HM Treasury, explains Why R&D Matters  
view
EBR's Editor, Helen Abbott, takes an in-depth look at the key lessons to be learnt from the review process for b-IFN treatment of multiple sclerosis patients in the UK, in her interview with two of the three product manufacturers (Serono and Schering), and the UK Multiple Sclerosis Society  
view
Anne-Toni Rodgers, Communications Director of the National Institute for Clinical Excellence (NICE), outlines NICE and the Technology Appraisal Process and presents the facts behind the NICE appraisal of beta-interferon  
view
bullet
Preview
EBR's Editor reviews BIO 2002, Toronto and the launch of CORDIA, Vienna  
bullet
BIOINFORMATICS
Is Data-Mining - The Magic Eye of Informatics? ask Dr Jonathan Heal, Director of Informatics, and Dr Jonathan Swinton, Senior Computational Biologist at Proteom Ltd  
view
Dr Jцrg Sprengel, Executive Project Director i-biology® at LION bioscience AG, examines The Pivotal Role of IT Systems in Drug Delivery and Innovation  
view
bullet
REGIONAL UPDATES
In Singapore - A World Class Hub for Biomedical Sciences, Tan Hsueh Mei at the Singapore Economic Development Board, introduces the 'Biopolis of Asia'

 
view
bullet
INTELLECTUAL PROPERTY AND TECH-TRANSFER
Daniel Pavin, a Solicitor Specialising in Intellectual Property and Information Technology Law with Taylor Joynson Garrett, is the bearer of Good News for European Bioinformatics - The Database Right  
view
bullet
DEVELOPMENT AND PRODUCTION
In Effective Gene Transfer in Neurobiology, Professor Alan Kingsman, Chief Executive Officer and Co-Founder of Oxford BioMedica plc, reviews the vectors available for gene therapy in neurobiological applications and examines potential gene therapy approaches for neurodegenerative disease and nerve regeneration  
view
Dr Salvatore Febbraro, Medical Director at Simbec Research Ltd, looks at Early Phase Clinical Trials of Biopharmaceuticals  
view
The issues involved in Post-Translational Modifications of Biopharmaceuticals - A Challenge for Analytical Characterisation are outlined by Dr Fiona Greer, Dr Andrew Reason and Dr Mark Rogers of M-Scan  
view
Dr Mark Bodmer, Chief Executive of Lorantis Ltd, examines the quest for the 'holy grail' of immunotherapy in Immunotherapy - From Suppression to Tolerance  
view
   
spacer
Edited by
Dr Deborah O'Neil,
Chief Executive and Scientific Officer,
NovaBiotics Ltd
Published quarterly in
January, April,
July and October

News and Press Releases

Oxford Genetics licenses SnapFast™ expression vectors to Twist Bioscience

November 16, 2017, Oxford, England and San Francisco, US. – Oxford Genetics, a leader in innovative synthetic biology-based technologies for biologics discovery, development and delivery, announced today a new licensing agreement with Twist Bioscience Corporation, a company enabling customers to succeed through its offering of rapid, high-quality synthetic DNA. Oxford Genetics will supply Twist Bioscience with its SnapFast™ technology platform to provide a broad range of application-specific expression vectors which Twist Bioscience will use to clone synthesized DNA for its diverse customer base.
More info >>

White Papers

Modular Feeding Systems for Prefilled Syringes and Injection Devices

Dividella

The pre-filled syringe and injection device is an increasingly attractive presentation for both new and established parenteral pharmaceuticals. We will explore how innovative carton packaging solutions can enhance this presentation whilst meeting the stringent requirements of product protection.
More info >>

Industry Events

INTERPHEX 2018

17-18 April 2018, Javits Center, New York, USA

At INTERPHEX, find all of the State-of-the-Art Solutions you need to Cost Effectively Develop and Manufacture Product. INTERPHEX is a premier pharmaceutical, biotechnology, and medical device development and manufacturing event and sponsored by Parenteral Drug Association (PDA).
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement